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Abstract: BACKGROUND: Psoriasis is a chronic inflammatory dermatosis characterized by erythematous, scaly
lesions covering extensive areas of the skin and negatively affecting patients’ quality of life by interfering in their
personal life, social relationships and routine activities. Treatment offers reasonable control of the condition;
however, little importance is generally given to the patient’s impression.  
OBJECTIVES: To evaluate the quality of life of patients with psoriasis, to verify whether there is a correlation bet-
ween quality of life and clinical improvement and to compare two quality of life questionnaires and evaluate their
equivalence.  
METHODS: Patients over 18 years of age attending the psoriasis outpatient clinic at the Teaching Hospital of the
University of Campinas (UNICAMP), who were either initiating treatment or changing to a new form of treatment,
were included in the study.  Patients answered two quality of life questionnaires (the Psoriasis Disability Index
and the Dermatological Life Quality Index) up to a total of 180 consultations to evaluate whether there is a cor-
relation between the questionnaires.  Patients were also rated using a clinical index (Psoriasis Area and Severity
Index) at baseline and at follow-up visits.  
RESULTS: The study involved 138 patients (76 men; mean age 50 years).  A correlation was found between the
questionnaires and the clinical index, showing that clinical changes are reflected in quality of life.  The two ques-
tionnaires were found to be equivalent.  
CONCLUSION: It was found that both clinical condition and quality of life improved in the majority of patients
receiving care at this outpatient clinic and that the quality of life questionnaires are equivalent.
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Resumo: FUNDAMENTO: A psoríase é uma dermatose inflamatória crônica caracterizada por lesões eritemato-des-
camativas que atingem extensas áreas da pele, comprometendo a qualidade de vida dos pacientes por interferir
na sua vida pessoal, no relacionamento social e nas atividades diárias. O tratamento permite um bom controle,
mas a impressão do paciente, quase sempre, é pouco valorizada. 
OBJETIVOS: Avaliar a qualidade de vida de pacientes psoriáticos, verificar se há correlação desta com melhoras clí-
nicas e se há equivalência entre dois questionários de qualidade de vida. 
MÉTODOS: Foram incluídos no estudo pacientes maiores de 18 anos que estavam no início ou troca de tratamen-
to no ambulatório de psoríase do Hospital de Clínicas da Unicamp. Eles responderam dois questionários de qua-
lidade de vida (Psoriasis Disability Index e Dermatological Life Quality Index), até completar 180 atendimentos,
para avaliar se haveria correlação entre os questionários. Receberam também um índice clínico (Índice de Área
e de Severidade da Psoríase) no tempo inicial da pesquisa e nos retornos subsequentes. 
RESULTADOS: A pesquisa foi realizada com 138 pacientes (76 homens, idade média de 50 anos). Observou-se cor-
relação entre os questionários aplicados e o índice clínico, mostrando que alterações clínicas se refletem na qua-
lidade de vida, e que há equivalência entre os questionários. 
CONCLUSÃO: Constatou-se que a maioria dos pacientes atendidos no ambulatório tem apresentado melhora clíni-
ca e da qualidade de vida e que há equivalência entre os questionários de qualidade de vida.
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Introduction
Patients with dermatological diseases, particu-
larly chronic diseases, perceive their health as being
affected, feel that the performance of their routine
activities is limited and experience a loss of vitality,
leading to the absences at school and work, in addition
to depression and, in some cases, social isolation. 
1
For example, psoriasis, in the majority of cases,
does not cause physical damage to the same extent as
chronic diseases such as hypertension or diabetes do;
however it affects quality of life (QoL) as much as or
even more than these diseases.  Patients with psoria-
sis have a degree of limitations similar to that of
patients with angina or hypertension; their physical
and mental function is reduced to the same extent as
that of patients with cancer, arthritis, hypertension,
cardiac disease and depression.  Furthermore, there is
an association with psychiatric diseases including sui-
cidal tendencies, with half of these patients express-
ing feelings of depression and anxiety with respect to
their diagnosis. 2
Psoriasis is a chronic, inflammatory, erythema-
tous-squamous dermatosis with periods of exacerba-
tion and remission.  The term psoriasis comes from
the Greek psora meaning “to itch” or an “eruption”.
The condition was first described by Celsus in the year
25 BC; however, it was confused with hanseniasis
until 1809 when Robert Willan described its various
clinical manifestations.  For this reason, it is also
known as Willan-Plumb syndrome. 3
It is characterized by an uncontrolled prolifera-
tion of keratinocytes, complex changes in the differenti-
ation of the epidermis and the attraction of T-cells to the
skin. It has the characteristics of an autoimmune dis-
ease.  Biochemical, immunological, inflammatory and
vascular abnormalities are involved in the process. 4
Its cause is unclear; however, various factors
are known to trigger or exacerbate the condition,
such as physical, chemical or surgical trauma, inflam-
mation, infections, stress and certain drugs (lithium,
beta-blockers, nonsteroidal antiinflammatory drugs,
etc.). 5 It is currently believed that even dietary habits
may constitute important factors in the pathogenesis
of this disease. 6 Genetic disposition is a determining
factor in the manifestation of the disease and has been
extensively studied in recent years, relatives of
patients with psoriasis having an increased risk of
developing the disease. 7.8
Typical lesions are erythematous-squamous,
clearly defined and covered with silvery-white, mica-
ceous scales.  They may be punctuated or follicular,
lenticular or drop-shaped, nummular, annular, serpig-
inous plaques of differing sizes.  Various forms may
coexist in the same individual.  They may be located
at any site on the skin surface, including the mucosa
but are generally found at extensor sites such as the
elbows, knees, the lumbar-sacral region and the scalp. 3
Since the lesion is often stigmatized, informa-
tion on the QoL of these patients is important, both
for the doctor-patient relationship and for public
awareness, in defining treatment and generating
healthcare policies. 2 It is also a crucial factor in ensur-
ing that the choice of therapy is not defined only on
the basis of technical knowledge but is individualized
so that the patient becomes involved in decisions
regarding his/her treatment in an attempt to increase
compliance with the proposed therapy. 9
The treatment should be in accordance with the
patient’s needs and should incur the least possible
risk to his/her health and QoL.  Mild forms of the dis-
ease may be treated topically, while the more exten-
sive forms, those resistant to treatment and the more
severe forms such as the arthropathic, erythrodermic
and pustular forms, require systemic treatment.
Treatment should be alternated between the different
therapeutical options in order to avoid tachyphylaxis
and side effects over the long term. 10 Nevertheless,
the current forms of treatment for moderate to severe
psoriasis are associated with toxicity in the short and
long term, as well as patient dissatisfaction. 11
The Dermatology Life Quality Index (DLQI) and
the Psoriasis Disability Index (PDI) were developed by
investigators in the United States and validated for use
in Brazilian Portuguese following authorization by the
authors. 12
The DLQI is a self-applicable questionnaire
developed by Fynlay and Khan in 1994 as a simplified
instrument to be used in clinical practice for applica-
tion in patients with skin diseases. 13 It consists of ten
questions, each one with four possible answers and a
score that ranges from 0 to 3 for each one (not at
all/not relevant = 0; a little = 1; a lot = 2 and very
much = 3). 12 This questionnaire evaluates symptoms
and feelings (Questions 1 and 2), daily activities
(Questions 3 and 4), leisure and sporting activities
(Questions 5 and 6), work and school (Question 7),
personal relationships (Questions 8 and 9) and treat-
ment (Question 10), resulting in a final score that
ranges from 0 to 30.  This score can also be grouped
in accordance with the impact on QoL (0-1 = no effect
at all on patient’s life; 2-5 = small effect; 6-10 = mod-
erate effect; 11-20 = very large effect; and 21-30 =
extremely large effect on patient’s life). 13.14
The PDI is an instrument used to evaluate the
QoL of patients with psoriasis, in which indicators of
the impact of the disease on lifestyle and daily routine
in specific areas are measured. 15 It consists of 15
questions divided into: daily activities (Questions 1-5),
school or work (Questions 6-8), personal relation-
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ships (Questions 9-10) and leisure (Questions 11-15).
Each question has four possible answers, receiving a
score of 0 to 3 (not at all = 0; a little = 1; a lot = 2;
very much = 3), resulting in a final score that ranges
from 0 to 45.
Clinical data on the extent of the disease were
obtained using the Psoriasis Area and Severity Index
(PASI), applied during consultation with the physi-
cian, for the purpose of obtaining an objective impres-
sion of the patient’s current clinical status. 13 Data are
collected on the most important clinical variables in
psoriasis (the area affected, erythema, infiltration and
desquamation), which are evaluated in accordance
with the region affected (head, trunk, upper or lower
limbs).  The area is evaluated in accordance with the
percentage of the body area affected and transformed
into a score that ranges from 0 (0% of the area affect-
ed) to 6 (90-100% of the area affected).  Erythema,
infiltration and desquamation are evaluated in accor-
dance with the severity of these clinical features, and
are awarded a score of 0-4 depending on whether the
feature is absent (0), mild (1), moderate (2), severe
(3) or very severe (4), resulting in a final index that,
theoretically, may range from 0 to 72. 16.17
Studies indicate that, although there is no corre-
lation between the absolute values of the PASI and
DLQI questionnaires, significant reductions in the PASI
are associated with an improvement in QoL (DLQI). 18
The objectives of the present study were to
evaluate the QoL of patients with psoriasis, to verify
whether there is a correlation between QoL and clini-
cal improvements, and to evaluate whether the two
QoL questionnaires (DLQI and PDI) are equivalent.
Material and Methods
A prospective study was conducted to evaluate
patients receiving care at the psoriasis clinic of the
Dermatology Department at the University of
Campinas (UNICAMP) Teaching Hospital.  Data collec-
tion began in February 2006 and finished in February
2009.
Patients over 18 years of age with a diagnosis of
psoriasis, who were initiating treatment with topic or
systemic medication for control of the condition or
were in the process of changing from one therapeutic
regimen to another, were included in the study.
The PASI questionnaire was applied by a physi-
cian during a medical consultation.  Evaluation of the
patient’s QoL was made by a second investigator on
the same day, immediately after the first consultation.
The same process was repeated at return visits.
To test the equivalence of the QoL question-
naires, they were applied at 180 consultations.  If the
two questionnaires were found to be equivalent, then
only the questionnaire that was simplest to apply
would be used for the remainder of the study period.
The charts of the patients who returned to the
clinic at least once after the baseline visit were evalu-
ated, including data on compliance with treatment,
the form of treatment, the period of use of the medica-
tion, other diseases, assiduity in attending consulta-
tions, improvement or deterioration in the patient’s
clinical status or quality of life, and side effects.
The data were analyzed using the SPSS statisti-
cal software program, version 16.0 (SPSS Inc.,
Chicago, Illinois, USA).  The mean, standard deviation,
range and quartiles were determined for age (years),
time (days) and PDI, DLQI and PASI scores.
Spearman’s correlation coefficient was used to assess
the association between the PDI, PASI and DLQI ques-
tionnaires.  Significance level was defined as 5%.
The project was approved by the Internal
Review Board of the School of Medical Sciences, UNI-
CAMP.  The patients invited to participate in the study
were only included after they had read and signed the
informed consent form.
Results
A total of 148 patients were included in the
study, resulting in the completion of 313 valid ques-
tionnaires, 148 of which were filled out at
baseline/time-point 0 (1st consultation), 86 at time-
point 1 (1st follow-up visit), 51 at time-point 2 (2nd fol-
low-up visit) and 28 questionnaires at time-point 3
(3rd follow-up visit).  Of the patients studied, 76 were
male and 62 female; 114 white, 20 brown and 4 black.
At the time of the final evaluation, patients’ age
ranged from 19 to 81 years, with a median of 53.5 years.
The time between completing the first and second ques-
tionnaires (baseline to time-point 1) ranged from 35 to
848 days (median 154 days), while the time between
time-points 1 and 2 ranged from 35 to 658 days (medi-
an 189 days) and the time between time-points 2 and 3
ranged from 35 to 553 days (median 224 days).  The dis-
tribution of these data is shown in Table 1.
Distribution of the DLQI, PDI and PASI scores
are shown in Table 2 and Figure 1.  A correlation was
found between the PASI and PDI scores, between the
DLQI and PDI scores and between the PASI and DLQI
values.  Spearman’s correlation coefficients are shown
in Table 3.
Discussion
Cross-analysis of the questionnaires
(Spearman’s correlation coefficient) showed that the
means obtained in the PDI and DLQI were strongly
correlated. This was expected, considering that,
although the first questionnaire is specific whereas the
second is generic, both deal with the QoL of patients
with dermatological lesions, in this particular case
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psoriasis.  The closer to 1 the result of Spearman’s
test, the higher the correlation between the question-
naires, 1 being the coefficient obtained when the rel-
evant questionnaires are identical.  Therefore, the cor-
relation between these two questionnaires was found
to be so high that the results found by one barely dif-
fered from those found with the other, i.e. they are
practically equivalent.  In view of this finding, it was
agreed that it would be feasible to use only one of
these questionnaires to evaluate the QoL of these
patients without any detriment.  The questionnaire
selected was the DLQI, since it is simpler and faster to
complete (with respect to the language used and the
number of questions).
A correlation was found between QoL and clin-
ical index, showing that clinical improvements are
reflected in an improvement in the effect of the dis-
ease on QoL and vice-versa.
In the final result, a significant improvement
was found in the scores of the patients who returned
to the clinic, a strong indication that the treatment
was effective.  A great improvement was seen at the
first follow-up visit, probably due to the effect of hav-
ing initiated treatment, together with the psychologi-
cal factor triggered by this fact.  At the second return
visit, there was little difference in the mean scores; in
fact, they were practically the same as those registered
at the first follow-up visit.  However, when cases were
evaluated individually, the moderate improvement
found in some patients was found to have been offset
by a moderate deterioration in others.  This may be
due to the end of the initial impact of treatment (end
of the psychological effect), since medication takes
some time to exert an effect that would effectively be
reflected in the symptomatology and to stabilize or
improve the lesions, leading to a certain degree of dis-
appointment and difficulty in achieving appropriate
compliance with treatment.  At the third follow-up
visit, an improvement is once again evident, probably
due to the prolonged and continuous action of the
medication.
Treatment progression tends to remain the
n Mean SD Min. 1st Quartile Median 3rd Quartile Max.
Age (years) 148 51.1 15.3 19 41.0 53.5 62.9 81
Time 1 (1) 86 218.0 186.1 35 84.0 154.0 274.7 848
Time 2 (2) 51 217.0 140.8 35 91.0 189.0 301.0 658
Time 3 (3) 28 230.25 148.4 35 113.7 224.0 320.2 553
TABLE 1: Distribution of patients according to age at the end of the study and time between return visits
n  = number of cases;  
(1) = time (in days) until 1st return visit;  
(2) = time (in days) between 1st and 2nd return visits;  
(3) = time (in days) between 2nd and 3rd return visits;
n Mean SD Min. 1st quartile Median 3rd quartile Max.
Baseline
PASI 148 12.5 10.6 0 4.8 10.5 17.0 57.0
DLQI 148 5.6 4.5 0 2.0 5.0 8.0 26.0
1st return visit
PASI 86 8.5 8.0 0 2.4 5.8 12.2 36.4
DLQI 86 2.9 3.1 0 1.0 2.0 5.0 14.0
2nd return visit
PASI 51 10.0 10.4 0 3.0 7.2 12.6 45.0
DLQI 51 3.1 4.0 0 0.5 2.0 3.5 15.0
3rd return visit
PASI 28 10.5 10.7 0 2.4 6.4 17.9 43.6
DLQI 28 3.7 3.9 0 1.0 2.0 6.5 13.0
TABLE 2: Distribution of patients according to PASI and DLQI scores throughout the study
n – number of cases;  
SD: standard deviation;
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same irrespective of the therapeutic options used (a
substantial improvement at the first return visit fol-
lowed by stabilization or a slight deterioration at the
second return visit and further improvement at the
third), which may be a consequence not only of a psy-
chological factor but also to the pattern of response to
the medication.
Conclusion
An improvement was found in the clinical con-
dition and quality of life of the majority of patients
receiving care at this clinic.  Since the two question-
naires were found to be equivalent, the DLQI then
began to be used alone in the routine of the psoriasis
clinic at UNICAMPs Teaching Hospital, both for
research purposes and for initial assessment and fol-
low-up of the patients. 
PASI DLQI
Baseline
PASI (n= 138) 1.000 0.423*
PDI  (n= 112) 0.416* 0.787*
1st return visit 
PASI (n= 82) 1.000 0.531*
PDI  (n= 53) 0.401* 0.606*
2nd return visit 
PASI (n= 43) 1.000 0.448*
PDI  (n= 15) 0.323* 0.775*
(*) – p < 0,05
TABLE 3: Spearman’s correlation coefficient for the
PASI, PDI and DLQI
FIGURE 1: Changes in clinical status and quality of life at the four
time-points in the study
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